BLFS

SEC source: 0001437749-20-012242 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,223

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-20-012245 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,064

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-20-012244 · rdgdoc.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Chief Revenue Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,856

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0001437749-20-012243 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 212,915

F1 · kind: The sale reported herein was made by the issuer to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

SEC source: 0000919574-20-003820 · ownership.xml · nonDerivative · entry 1

Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner

Casdin Capital, LLC · CIK 0001534261 · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · 10% owner

Casdin Eli · CIK 0001534264 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,849,524

F1 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0001437749-20-012378 · rdgdoc.xml · nonDerivative · entry 5

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus4757 GmbH

Disclosed balance after: 1,948,357

SEC source: 0001437749-20-011068 · rdgdoc.xml · derivative · entry 6

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 187,500

Underlying: Common Stock · 18,750 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-011068 · rdgdoc.xml · nonDerivative · entry 4

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,739

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 15, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.83 to $14.96 inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-20-011068 · rdgdoc.xml · nonDerivative · entry 3

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-011067 · rdgdoc.xml · derivative · entry 3

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 199,837

Underlying: Common Stock · 10,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-011067 · rdgdoc.xml · nonDerivative · entry 2

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,157

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.04 to $14.96, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-20-011067 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000919574-20-003747 · ownership.xml · nonDerivative · entry 1

Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner

Casdin Capital, LLC · CIK 0001534261 · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · 10% owner

Casdin Eli · CIK 0001534264 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,373,333

F1 · kind: On May 14, 2020, Casdin Partners Master Fund, LP entered into a Share Purchase Agreement with the Issuer for the purchase of the securities reported herein, with a closing date of May 26, 2020 and subject to certain conditions as set forth in the Share Purchase Agreement.

F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, LP and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, LP, (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund LP, and (ii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0001437749-20-010644 · rdgdoc.xml · derivative · entry 6

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,837

Underlying: Common Stock · 10,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 4

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,157

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.38 to $15.48, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 3

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-011068 · rdgdoc.xml · derivative · entry 5

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 206,250

Underlying: Common Stock · 18,750 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-011068 · rdgdoc.xml · nonDerivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,739

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 15, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.38 to $15.48, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-20-011068 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-012379 · rdgdoc.xml · derivative · entry 7

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 0

Underlying: Common Stock · 550,000 shares

Expires 2021-05-12

F2 · kind: On May 13, 2020, the reporting person exercised an in-the-money warrant to purchase 550,000 shares of Common Stock of the Company with an exercise price of $1.75 per share pursuant to Rule 16b-6 under the Exchange Act. The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 64,597 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 485,403 shares.

F4 · price: The warrants were issued to WAVI in May 2016 as partial consideration of a loan transaction.

SEC source: 0001437749-20-012379 · rdgdoc.xml · derivative · entry 6

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 0

Underlying: Common Stock · 1,777,211 shares

Expires 2021-03-25

F1 · kind: On May 13, 2020, WAVI Holding AG ("WAVI"), an entity wholly owned by Walter Villiger (together, the "reporting person"), exercised an in-the-money warrant to purchase 1,777,211 shares of common stock, par value $0.001 per share (the "Common Stock"), of Biolife Solutions, Inc. (the "Company") with an exercise price of $4.75 per share pursuant to Rule 16b-6 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 566,561 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,210,650 shares.

F3 · price: The warrants were issued to WAVI in March 2014 in connection with the conversion of outstanding promissory notes and interest accrued thereon for units consisting of common stock and warrants.

SEC source: 0001437749-20-012379 · rdgdoc.xml · nonDerivative · entry 5

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 5,011,639

F2 · kind: On May 13, 2020, the reporting person exercised an in-the-money warrant to purchase 550,000 shares of Common Stock of the Company with an exercise price of $1.75 per share pursuant to Rule 16b-6 under the Exchange Act. The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 64,597 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 485,403 shares.

SEC source: 0001437749-20-012379 · rdgdoc.xml · nonDerivative · entry 4

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 5,076,236

F2 · kind: On May 13, 2020, the reporting person exercised an in-the-money warrant to purchase 550,000 shares of Common Stock of the Company with an exercise price of $1.75 per share pursuant to Rule 16b-6 under the Exchange Act. The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 64,597 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 485,403 shares.

SEC source: 0001437749-20-012379 · rdgdoc.xml · nonDerivative · entry 3

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 4,526,236

F1 · kind: On May 13, 2020, WAVI Holding AG ("WAVI"), an entity wholly owned by Walter Villiger (together, the "reporting person"), exercised an in-the-money warrant to purchase 1,777,211 shares of common stock, par value $0.001 per share (the "Common Stock"), of Biolife Solutions, Inc. (the "Company") with an exercise price of $4.75 per share pursuant to Rule 16b-6 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 566,561 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,210,650 shares.

SEC source: 0001437749-20-012379 · rdgdoc.xml · nonDerivative · entry 2

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 5,092,797

F1 · kind: On May 13, 2020, WAVI Holding AG ("WAVI"), an entity wholly owned by Walter Villiger (together, the "reporting person"), exercised an in-the-money warrant to purchase 1,777,211 shares of common stock, par value $0.001 per share (the "Common Stock"), of Biolife Solutions, Inc. (the "Company") with an exercise price of $4.75 per share pursuant to Rule 16b-6 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 566,561 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,210,650 shares.

SEC source: 0001437749-20-012378 · rdgdoc.xml · derivative · entry 7

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus4757 GmbH

Disclosed balance after: 0

Underlying: Common Stock · 1,544,194 shares

Expires 2021-03-25

F2 · kind: On May 13, 2020, the reporting person exercised an in-the-money warrant to purchase 1,544,194 shares of Common Stock of the Company for $4.75 per share pursuant to Rule 16b-6 under the Securities Exchange Act of 1934, as amended. The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 492,277 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,051,197 shares.

F3 · price: The warrants were issued to Taurus in March 2014 in connection with conversion of outstanding promissory notes and interest accrued thereon for units consisting of common stock and warrants.

SEC source: 0001437749-20-012378 · rdgdoc.xml · nonDerivative · entry 4

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus4757 GmbH

Disclosed balance after: 2,424,548

F2 · kind: On May 13, 2020, the reporting person exercised an in-the-money warrant to purchase 1,544,194 shares of Common Stock of the Company for $4.75 per share pursuant to Rule 16b-6 under the Securities Exchange Act of 1934, as amended. The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 492,277 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,051,197 shares.

SEC source: 0001437749-20-012378 · rdgdoc.xml · nonDerivative · entry 3

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus4757 GmbH

Disclosed balance after: 2,916,825

F2 · kind: On May 13, 2020, the reporting person exercised an in-the-money warrant to purchase 1,544,194 shares of Common Stock of the Company for $4.75 per share pursuant to Rule 16b-6 under the Securities Exchange Act of 1934, as amended. The reporting person exercised the warrant on a cashless basis pursuant to the terms of the warrant, resulting in the Company's withholding of 492,277 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 1,051,197 shares.

SEC source: 0001437749-20-010644 · rdgdoc.xml · derivative · entry 5

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 219,837

Underlying: Common Stock · 10,000 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 2

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,157

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 12, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.37 to $13.41, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-20-010644 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 223,157

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-007796 · rdgdoc.xml · derivative · entry 6

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 225,000

Underlying: Common Stock · 18,750 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-007796 · rdgdoc.xml · nonDerivative · entry 4

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,739

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 15, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.53 to $9.81 inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-20-007796 · rdgdoc.xml · nonDerivative · entry 3

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-007796 · rdgdoc.xml · derivative · entry 5

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,750

Underlying: Common Stock · 18,750 shares

Expires 2025-05-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-007796 · rdgdoc.xml · nonDerivative · entry 2

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 214,739

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of May 15, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.94 to $9.30, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

SEC source: 0001437749-20-007796 · rdgdoc.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 233,489

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001437749-20-006399 · rdgdoc.xml · derivative · entry 5

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,718

Underlying: Common Stock · 13,718 shares

Expires not disclosed

F5 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus.

F5 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-20-006399 · rdgdoc.xml · derivative · entry 4

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,863

Underlying: Common Stock · 22,863 shares

Expires not disclosed

F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-20-006399 · rdgdoc.xml · nonDerivative · entry 3

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 213,157

F3 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

F3 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

SEC source: 0001437749-20-006399 · rdgdoc.xml · nonDerivative · entry 2

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 190,294

F2 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

F2 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

SEC source: 0001437749-20-006399 · rdgdoc.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Exec VP & Chief Scientific Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 184,706

F1 · security: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus.

F1 · price: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus.

SEC source: 0001437749-20-006398 · rdgdoc.xml · derivative · entry 5

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,651

Underlying: Common Stock · 11,651 shares

Expires not disclosed

F5 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus.

F5 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-20-006398 · rdgdoc.xml · derivative · entry 4

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,418

Underlying: Common Stock · 19,418 shares

Expires not disclosed

F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-20-006398 · rdgdoc.xml · nonDerivative · entry 3

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,234

F3 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

F3 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

SEC source: 0001437749-20-006398 · rdgdoc.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,816

F2 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

F2 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

SEC source: 0001437749-20-006398 · rdgdoc.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,070

F1 · security: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus.

F1 · price: The restricted stock pursuant to the BioLife Solutions 2013 Performance Incentive Plan (as amended, the "Plan") and vests in full on September 25, 2020. This restricted stock was granted to the reporting person in lieu of such reporting person's 2019 cash performance bonus.

SEC source: 0001437749-20-006397 · rdgdoc.xml · derivative · entry 5

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,154

Underlying: Common Stock · 13,154 shares

Expires not disclosed

F5 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus.

F5 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2020 and will vest as to between 0% and 125% of the reported number of shares in column 5 based on the reporting person's performance during the 2020 fiscal year, as determined by the registrant's board of directors. This restricted stock was granted in lieu of such reporting person receiving a 2020 cash performance bonus.

SEC source: 0001437749-20-006397 · rdgdoc.xml · derivative · entry 4

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,923

Underlying: Common Stock · 21,923 shares

Expires not disclosed

F4 · derivative.exercise_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

F4 · derivative.expiration_date: The restricted stock was granted pursuant to the Plan. The restricted stock will vest on the date that the registrant files its Annual Report on Form 10-K for the fiscal year ended 2021 and will vest as to between 0% and 200% of the reported number of shares in column 5 based on the registrant's total shareholder return during the period beginning on January 1, 2020 through December 31, 2021 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

SEC source: 0001437749-20-006397 · rdgdoc.xml · nonDerivative · entry 3

DE GREEF RODERICK · CIK 0001241181 · CFO & COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,074

F3 · security: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.

F3 · price: The restricted stock was granted pursuant to the Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2020 compensation.